Seres Therapeutics, Inc. Income Statement
MCRB|10 years of annual SEC 10-K data (FY2015-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$0
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$195M
FY2025
Net Income
-$114M
FY2025
Seres Therapeutics, Inc. reported $0 in revenue and $114M in net loss for FY2025. Revenue has grown at a 31.1% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $144.9M | $33.2M | $34.5M | $28.3M | $32.1M | $21.8M | $21.8M | $21.8M | $0 |
| SG&A Expense | $77.5M | $69.3M | $30.8M | $24.7M | $32.6M | $34.0M | $32.6M | $16.8M | $4.4M | $1.2M |
| R&D Expense | $117.6M | $141.9M | $90.6M | $80.1M | $96.0M | $89.5M | $82.0M | $38.1M | $10.7M | $4.8M |
| Operating Income | -$195.1M | -$64.5M | -$88.1M | -$71.9M | -$100.3M | -$91.4M | -$92.8M | -$54.9M | -$15.1M | -$6.1M |
| Interest Expense | $2.5M | $2.9M | $2.9M | $502.0K | $502.0K | $502.0K | - | $83.0K | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$113.7M | -$65.6M | -$89.1M | -$70.3M | -$98.9M | -$89.4M | -$91.6M | -$54.8M | -$16.7M | -$6.1M |
| EPS (Basic) | -$17.77 | -$0.72 | -$1.12 | - | - | - | - | - | - | - |
| EPS (Diluted) | -$17.77 | -$0.72 | -$1.12 | -$1.24 | -$2.43 | -$2.21 | -$2.30 | -$2.33 | -$2.67 | -$1.09 |
| Shares Outstanding | 8.7M | 125.2M | 91.9M | 91.5M | 70.1M | 40.9M | 40.6M | 40.4M | 39.1M | 6.9M |
| Operating Margin | - | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% | -252.0% | -69.3% | - |
| Profit Margin | - | -45.3% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% | -251.7% | -76.8% | - |